【佳学基因检测】转录因子 MAFB 基因检测对肺腺癌的治疗的预后分析

2022年靶向药价格一览表—目的

课题调研《肿瘤基因突变度与预防策略的实施计划》《Int J Mol Sci》在. 2022 Sep 1;23(17):9945.发表了一篇题目为《转录因子 MAFB 作为肺腺癌的预后生物标志物》肿瘤靶向药物治疗基因检测临床研究文章。该研究由Omar Samir, Naohiro Kobayashi, Teppei Nishino, Mennatullah Siyam, Manoj Kumar Yadav, Yuri Inoue, Satoru Takahashi, Michito Hamada等完成。促进了肿瘤的精准治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤靶向药物及精准治疗临床研究内容关键词：

MAFB,生物标志物,癌症预后,癌症严重程度,肿瘤相关巨噬细胞

肿瘤靶向治疗基因检测临床应用结果

MAFB 是一种在巨噬细胞中特异性表达的碱性亮氨酸拉链 (bZIP) 转录因子。肺腺癌预后分析基因检测研究团队之前已将 MAFB 鉴定为人和小鼠模型中肿瘤相关巨噬细胞 (TAM) 的候选标记物。在这里，肺腺癌预后分析基因检测研究团队分析了从 GEO 数据库 (GSE131907) 获得的肺腺癌患者的单细胞测序数据。分析数据表明，一般巨噬细胞标志物CD68和巨噬细胞清除受体1（CD204）在TAM和肺组织巨噬细胞簇中表达，而转录因子MAFB在TAM簇中特异性表达。从日本筑波大学医院的筑波人体组织生物库中心 (THB) 检索了 120 名 I 期 (n = 57)、II (n = 21) 和 III (n = 42) 期肺腺癌患者的临床记录。提取这些患者的肿瘤组织并用抗人 MAFB 抗体染色，然后对相对于组织面积（MAFB+ 细胞/组织面积）的 MAFB 阳性细胞进行形态学定量。我们的研究结果表明，较高数量的 MAFB+ 细胞与增加的局部淋巴结转移（淋巴结受累）、高复发率、较差的病理分期、增加的淋巴渗透、较高的血管浸润和胸膜浸润显着相关。此外，MAFB+细胞数量的增加与较差的总体存活率和无病存活率有关，尤其是在吸烟者中。这些数据表明，MAFB 可能是吸烟肺癌患者的一种合适的预后生物标志物。生物标志物；癌症预后；癌症严重程度；肿瘤相关巨噬细胞。

肿瘤发生与复发转移国际数据库描述：

MAFB is a basic leucine zipper (bZIP) transcription factor specifically expressed in macrophages. We have previously identified MAFB as a candidate marker for tumor-associated macrophages (TAMs) in human and mouse models. Here, we analyzed single-cell sequencing data of patients with lung adenocarcinoma obtained from the GEO database (GSE131907). Analyzed data showed that general macrophage marker CD68 and macrophage scavenger receptor 1 (CD204) were expressed in TAM and lung tissue macrophage clusters, while transcription factor MAFB was expressed specifically in TAM clusters. Clinical records of 120 patients with lung adenocarcinoma stage I (n = 57), II (n = 21), and III (n = 42) were retrieved from Tsukuba Human Tissue Biobank Center (THB) in the University of Tsukuba Hospital, Japan. Tumor tissues from these patients were extracted and stained with anti-human MAFB antibody, and then MAFB-positive cells relative to the tissue area (MAFB+ cells/tissue area) were morphometrically quantified. Our results indicated that higher numbers of MAFB+ cells significantly correlated to increased local lymph node metastasis (nodal involvement), high recurrence rate, poor pathological stage, increased lymphatic permeation, higher vascular invasion, and pleural infiltration. Moreover, increased amounts of MAFB+ cells were related to poor overall survival and disease-free survival, especially in smokers. These data indicate that MAFB may be a suitable prognostic biomarker for smoker lung cancer patients.Keywords: MAFB; biomarker; cancer prognosis; cancer severity; tumor-associated macrophages.